Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls

Trop-2 is an ideal candidate for targeted therapeutics because it is a transmembrane protein with an extracellular domain overexpressed in a wide variety of tumors, and is upregulated in normal cells. Consequently, several Trop-2-targeted drugs have recently been developed for clinical use, such as...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sara Bravaccini, Roberta Maltoni
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
R
Accès en ligne:https://doaj.org/article/1969c0c6d1fe4cd3bb52879c006c3111
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!